Sector
PharmaceuticalsOpen
₹288.2Prev. Close
₹293.25Turnover(Lac.)
₹4,866.19Day's High
₹304.2Day's Low
₹27852 Week's High
₹052 Week's Low
₹0Book Value
₹0Face Value
₹2Mkt Cap (₹ Cr.)
4,861.2P/E
200.7EPS
1.5Divi. Yield
0.33No Record Found
Y/e 31 Mar( In .Cr) | Mar-2016 | Mar-2015 | Mar-2014 | Mar-2013 |
---|---|---|---|---|
Equity Capital | 16.14 | 16.14 | 16.14 | 16.14 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 895.36 | 820.29 | 780.94 | 709.28 |
Net Worth | 911.5 | 836.43 | 797.08 | 725.42 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2016 | Mar-2015 | Mar-2014 | Mar-2013 |
---|---|---|---|---|
Revenue | 510.39 | 492.24 | 473.28 | 484.63 |
yoy growth (%) | 3.68 | 4 | -2.34 | 4.58 |
Raw materials | -193.84 | -213.87 | -175.64 | -179.19 |
As % of sales | 37.97 | 43.44 | 37.11 | 36.97 |
Employee costs | -65.89 | -58.88 | -58.37 | -58.21 |
Y/e 31 Mar( In .Cr) | Mar-2016 | Mar-2015 | Mar-2014 | Mar-2013 |
---|---|---|---|---|
Profit before tax | 120.25 | 103.82 | 118.83 | 94.7 |
Depreciation | -44.25 | -44.13 | -44.13 | -35.34 |
Tax paid | -33.1 | -45.34 | -32.04 | -31.52 |
Working capital | 85.06 | 133.26 | -3.47 | 130.15 |
Other operating items |
Y/e 31 Mar | Mar-2016 | Mar-2015 | Mar-2014 | Mar-2013 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 3.68 | 4 | -2.34 | 4.58 |
Op profit growth | 15.25 | -15.91 | 4.15 | 16.71 |
EBIT growth | 9.86 | -8.56 | 27.54 | 17.88 |
Net profit growth | 49.02 | -32.61 | 37.37 | 40.9 |
Particulars (Rupees in Crores.) | Mar-2017 | Mar-2016 | Mar-2015 | Mar-2014 | Mar-2013 |
---|---|---|---|---|---|
Gross Sales | 1,633.86 | 1,561.85 | 1,560.35 | 1,373.23 | 1,267.56 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,633.86 | 1,561.85 | 1,560.35 | 1,373.23 | 1,267.56 |
Other Operating Income | 79.83 | 34.2 | 28.39 | 12.07 | 4.65 |
Other Income | 26.13 | 26.54 | 86.91 | 24.87 | 17.78 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,819 | 158.19 | 4,36,103.12 | 863.29 | 0.74 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,782.35 | 83.58 | 1,53,540.39 | 518 | 0.52 | 2,302 | 513.62 |
Mankind Pharma Ltd MANKIND | 2,910.6 | 59.91 | 1,20,073.47 | 634.43 | 0 | 2,529.74 | 334.18 |
Cipla Ltd CIPLA | 1,475.75 | 28.16 | 1,19,195.76 | 1,178.16 | 0.88 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,399.45 | 70.36 | 1,15,106.89 | 460 | 0.82 | 2,376 | 222.38 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
JANMEJAY RAJNIKANT VYAS
Whole-time Director
DEOHOOTI JANMEJAY VYAS
Director
ASHOK CHANDRAKANT GANDHI
Director
RAJENDRA SHANTILAL SHAH
Director
SANJAY SHAILESHBHAI MAJMUDAR
Managing Director & CFO
ARPIT JANMEJAY VYAS
Director
SUBIR KUMAR DAS
Director
MARK CHRISTOPHER GRIFFITHS
Company Secretary
SHRIMA GAURANGBHAI DAVE
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Dishman Pharmaceuticals and Chemicals Ltd Merged
Summary
Dishman Pharmaceuticals and Chemicals Ltd is a recognized supplier of cost-effective, high quality chemical services and products to the global pharmaceutical and chemical industry. They are involved in the manufacture of active pharmaceutical ingredients (API), API intermediates, quaternary ammonium compounds and fine chemicals. They are having their manufacturing facility at Ahmedabad in Gujarat. Dishman Pharmaceuticals and Chemicals Ltd was incorporated in the year 1983 as a research-oriented organization. The company set up their first manufacturing unit in Naroda for phase Transfer Catalysts. The company earned the status of Quat Company by establishing themselves in the quat business.In the year 1995, the company formed a joint venture company with Schtz & Co, Germany called as Schutz Dishman Biotech Private Ltd. They manufacture Chlorhexidine Base, Chlorhexidine HCl, Chlorhexidine Acetate and Chlorhexidine Gluconate solution, for the European market. In the year 1997, the company commenced their production in the unit I at Bavla.In the year 1998, the company established marketing subsidiaries Dishman Europe in London and Dishman USA in Middlesex New Jersey. In the year 2001, they signed the first contract manufacturing project. The company converted their entire Bavla facility into 100% Export oriented Unit in the year 2003. Also, they acquired Chemconserve BV in Netherland.In April 2004, the company incorporated a wholly owned subsidiary company namely Dishman Interna
Read More
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice